Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 5, 2004, Pages 459-466

  Akamatsu, Masatoshi ^a   Yoshida, Haruhiko ^a,b   Shiina, Shuichiro ^a   Teratani, Takuma ^a   Tateishi, Ryosuke ^a   Obi, Shuntaro ^a   Sato, Shinpei ^a   Koike, Yukihiro ^a   Fujishima, Tomonori ^a   Ishikawa, Takashi ^a   Shiratori, Yasushi ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Hepatitis C virus genotype; Hepatitis C virus virus load; Hepatocellular carcinoma; Recurrence; Survival

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTERY EMBOLISM; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMAGING SYSTEM; INJECTION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROWAVE RADIATION; NONBIOLOGICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; VIRAL LOAD;

EID: 2342481130     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200405000-00004     Document Type: Article

References (39)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
2. Reid AE, Koziel MJ, Aiza I, Jeffers L, Roddy R, Schiff E, et al. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Am J Gastroenterol 1999; 94:1619-1626.
3. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1996; 21:650-655.
4. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18:16-20.
5. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338:914-915.
6. Cheung RC, Chan RT, Lok AS. Longitudinal study of hepatitis C viremia in chronic hepatitis C. J Med Virol 1993; 41:338-342.
7. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-524.
8. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19:1088-1094.
9. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 1990; 86:1764-1767.
10. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122:161-168.
11. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996; 111:199-205.
12. Brechot C. Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma. Hepatology 1997; 25:772-774.
13. Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 1996; 88:742-746.
14. Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 1992; 14:35-40.
15. Hatzakis A, Katsoulidou A, Kaklamani E, Touloumi G, Koumantaki Y, Tassopoulos NC, et al. Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int J Cancer 1996; 68:51-53.
16. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23:695-699.
17. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108:1088-1096.
18. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.
19. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24:1003-1009.
20. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994; 39:234-239.
21. Romeo R, Colombo M, Rumi M, Soffredini R, Del Ninno E, Donato MF, et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 1996; 3:183-190.
22. Yotsuyanagi H, Koike K, Yasuda K, Moriya K, Hino K, Kurokawa K, et al. Hepatitis C virus genotypes and development of hepatocellular carcinoma. Cancer 1995; 76:1352-1355.
23. Romeo R, Rumi MG, Del Ninno E, Colombo M. Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma [Letter]. Hepatology 1997; 26:1077.
24. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24:1041-1046.
25. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus - an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32:1216-1223.
26. Edmondson H, Steiner P. Primary carcinoma of the liver. Cancer 1954; 7:462-503.
27. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
28. Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74:2385-2390.
29. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19:1347-1353.
30. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol 1993; 160:1023-1028.
31. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91:561-569.
32. Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88:1557-1564.
33. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25:754-758.
34. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29:1124-1130.
35. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
36. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocelular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174-181.
37. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Characteristics and course of small hepatocellular carcinomas in patients with hepatitis C virus types 1 and 2. J Med Virol 2001; 63:120-127.
38. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228-232.
39. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134:963-967.